公司資料
Allarity Therapeutics 股價、新聞與催化劑
- 股票代碼:
- ALLR
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Denmark
股票表現
1.34 USD (-2.19%)
收盤價
最後更新: 2026年8月17日
26.9M USD
市值
股價為何變動
The latest company update was “Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign”. ALLR changed 0.74% and closed at $1.37 on Aug 14, 2026, indicating a relatively limited closing-price reaction to this clinical readout update.
公司概覽
Biomarker-Guided Oncology
Allarity Therapeutics develops personalized cancer therapies paired with drug-specific companion diagnostics. Its strategy is to identify patients whose tumor gene-expression profiles indicate a higher probability of responding to a particular anticancer medicine.
Stenoparib
Stenoparib is an oral small molecule that inhibits PARP1/2 and tankyrase1/2. This dual mechanism combines DNA-damage interference with inhibition of WNT/beta-catenin signaling, a pathway associated with tumor progression, metastasis, and drug resistance. Allarity holds exclusive global development and commercialization rights to the candidate.
DRP Companion Diagnostic
The Drug Response Predictor platform analyzes messenger-RNA expression patterns from tumor biopsies to generate a drug-specific response score. Allarity is developing a stenoparib-specific DRP companion diagnostic to enrich clinical studies for patients most likely to benefit and operates a CLIA-certified laboratory capable of performing the testing for US trials.
Ovarian-Cancer Development
Stenoparib is being evaluated in a Phase 2 study for advanced recurrent ovarian cancer that is platinum-resistant or platinum-ineligible. The program has FDA Fast Track designation, and the completed late-stage manufacturing campaign provides drug supply suitable for a future registrational trial.
Additional Tumor Programs
A Department of Veterans Affairs-funded Phase 2 study is evaluating stenoparib with temozolomide in relapsed small-cell lung cancer. Preclinical findings also support potential development in colorectal cancer through inhibition of WNT pathway signaling.
未來催化劑
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。